SABCS

1 stories · following the connections

Business

Cascadian Therapeutics Amends HER2CLIMB Phase 2 Trial of Tucatinib in Metastatic HER2-Positive Breast Cancer to Support Registration

By Nasdaq OMXDec 7, 2016, 12:00 PM UTC